mTOR Regulation of Metabolism in Hematologic Malignancies
Neoplastic cells rewire their metabolism, acquiring a selective advantage over normal cells and a protection from therapeutic agents. The mammalian Target of Rapamycin (mTOR) is a serine/threonine kinase involved in a variety of cellular activities, including the control of metabolic processes. mTOR...
Main Authors: | Simone Mirabilii, Maria Rosaria Ricciardi, Agostino Tafuri |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/2/404 |
Similar Items
-
mTOR Regulation of Glycolytic Metabolism in T Cells
by: Robert J. Salmond
Published: (2018-09-01) -
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
by: Zhilin Zou, et al.
Published: (2020-03-01) -
Editorial: Linking cellular metabolism to hematological malignancies
by: Xiujing He, et al.
Published: (2022-11-01) -
The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside
by: Yimei Feng, et al.
Published: (2021-01-01) -
mTOR hyperactivity and RICTOR amplification as targets for personalized treatments in malignancies
by: Dániel Sztankovics, et al.
Published: (2024-03-01)